Vendor Intelligence Report: Elite Research USA
Published 12 Nov 2026. 31-page investigative report on who is behind Elite Research USA: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.
Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.
Executive summary
Elite Research USA is verifiable but uneven. Across 51 Finnrick lab tests, the record is 24 pass / 27 fail, a 47% overall pass rate. Retatrutide and Tirzepatide sit on the stronger side; CJC-1295 is the clearest poor performer, and BPC-157 is weak despite live BPC listings. This is a product-selection and lot-verification problem, not a simple vendor-wide verdict, and stricter grading compresses the scores.
The operating footprint is more developed than many gray-market storefronts. Texas franchise-tax records point to a Wyoming LLC, a named 2026 corporate officer, and an active Texas-facing account, while the .shop domain now redirects to the .com storefront. The store is login-gated for normal visitors, but affiliate codes open a timed preview exposing product pages, prices, and COAs. The archive is broad, but COAs do not reveal manufacturer, filler, or release authority.
The control story is still incomplete. Public materials do not resolve beneficial ownership; Wayne Walls and DOOKS / @trinity2pointO are the strongest visible operator signals. Code-linked promotion runs through X, the 100 Club, and Texas Takeover, with disclosure quality varying by promoter. Retatrutide shows why the full file matters: a strong aggregate product became a lot-verification warning after a public COA trail, a conflicting field certificate, and later delisting pointed in different directions.
Inside the full report:
- Per-product Finnrick pass/fail rates, methodology-divergence charts, and spark-grid trajectories for all seven tested products
- Texas Comptroller record for ELITE RESEARCH USA LLC, including taxpayer, FEI, mailing address, 2026 PIR officer, and Texas SOS posture
- Affiliate guest-pass walkthrough of the login-gated catalog, price exposure, and COA object access
- COA archive audit reconciling storefront documents with PeptideBenchmark, Freedom Diagnostics, SyntheSyx, BioRegen, and Vanguard signals
- Retatrutide timeline covering Wayback captures, COA entries and removals, the field-certificate conflict, and 404 status
- Affiliate-network and recourse analysis covering X promoters, 100 Club / Texas Takeover, payment references, and reseller-confusion risk
Risk assessment
- CJC-1295 quality risk — high: CJC-1295 is Elite’s weakest tested product at 21.32% with 1 pass / 9 fail; standalone pages are 404 but a CJC-1295/IPA blend remains live and is not validated by Finnrick’s CJC record.
- BPC-157 quality risk — high: BPC-157 remains live across multiple SKUs while Finnrick records 44.91% with 3 pass / 7 fail, requiring exact lot COA verification and preferably independent testing.
- Delisted GLP-1/GH catalog risk — medium: Retatrutide has Elite’s best rating at 77.66% but is 404 with prior public COAs disappeared; Mazdutide is 48.92% with 0 pass / 3 fail and is also 404, so any reappearance should be treated as a new lot.
- Affiliate-promotion risk — medium: Elite’s active code network and 100 Club/Texas Takeover hub include disclosed and unclear paid promotions; code-linked praise should be treated as advertising.
- Brand-authentication / reseller-confusion risk — medium: Elite publishes no official-channel or authorized-reseller list; .shop redirects to .com and stale third-party pages still list delisted products such as Retatrutide.
- Corporate-recourse risk — medium: Texas Comptroller account is active but shows Texas SOS NOT REGISTERED and registered agent Not on File; UBO remains unresolved in public records.
- Label-control / customer-incident risk — medium: The tiny Trustpilot sample includes a claimed DMAA-for-Enclomiphene shipment and an underdosed-HCG support complaint; not independently verified, but safety-relevant.